Healthcare · NIFTY 500
Zydus Lifesciences Limited
NSEZYDUSLIFE
BSE532321 ISININE010B01027 SeriesEQ Listed on NSE · BSE
₹1,206.00 +6.50 (+0.54%) Updated 12 Nov, 9:19 pm IST
Price, daily close+23.28% in a year
Today
- Open
- ₹1,199.40
- Prev close
- ₹1,199.50
- Day high
- ₹1,209.20
- Day low
- ₹1,193.90
- Volume
- 19.78 L
- Value traded
- ₹237.41 Cr
- Upper circuit
- ₹1,240.20
- Lower circuit
- ₹1,168.00
- 52W high
- ₹1,266.60
- 52W low
- ₹835.50
- 1 month
- +7.72%
- 6 months
- +25.18%
52W low52W high
Ratios
Key numbers
Worked out from the latest filings (Consolidated) and today's price. TTM = last four quarters.
Market cap₹120,359 Cr
P/E (TTM)28.96
P/B4.33
Book value / share₹278.73
EPS (TTM)₹41.64
ROE15.0%
Dividend yield0.08%
Dividend (12m)₹1.00 / share
Net margin (TTM)13.8%
Operating margin24.0%
Debt / equity0.48
Current ratio1.02
EV / EBITDA17.28
Sales growth (YoY qtr)+29.17%
Profit growth (YoY qtr)-26.47%
Sales CAGR 3Y+16.35%
Profit CAGR 3Y+36.99%
Shares99.80 Cr
Quarterly results
Results for each quarter
Last 12 quarters, consolidated, ₹ crore. Hover a bar to see the number.
Revenue and net profit
Dec 23
Mar 24
Jun 24
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
Revenue · QoQ (vs last quarter)
—+23%+12%-16%+0.6%+24%+0.7%-6.9%+12%+11%+5.7%-1.3%
Revenue · YoY (vs a year ago)
————+17%+18%+5.9%+17%+30%+16%+22%+29%
Net profit · QoQ (vs last quarter)
—-92%+2,126%-36%+12%-93%+1,915%-14%-17%+22%-26%-1.5%
Net profit · YoY (vs a year ago)
————+30%+14%+3.3%+38%+1.8%+1,648%-36%-26%
RevenueNet profitLine = trend
Dec 23
Mar 24
Jun 24
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
EPS (₹) · YoY (vs a year ago)
————+30%-0.4%+3.3%+38%+1.9%+8.7%-36%-26%
EPS (₹)Line = trend
| ₹ Cr | Dec 23 | Mar 24 | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Sep 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4,505 | 5,534 | 6,208 | 5,237 | 5,269 | 6,528 | 6,574 | 6,123 | 6,865 | 7,587 | 8,017 | 7,910 |
| Other income | 37.7 | 156 | 63.2 | 68.2 | 57.5 | 80.6 | 155 | 109 | 111 | 134 | 106 | 130 |
| Total income | 4,543 | 5,690 | 6,271 | 5,305 | 5,327 | 6,609 | 6,729 | 6,232 | 6,976 | 7,721 | 8,123 | 8,040 |
| Raw material | 1,063 | 1,210 | 1,116 | 1,067 | 1,027 | 1,164 | 1,219 | 1,327 | 1,216 | 1,347 | 1,251 | 1,387 |
| Purchases | 459 | 543 | 522 | 484 | 571 | 573 | 658 | 589 | 852 | 972 | 1,289 | 1,260 |
| Employee cost | 817 | 837 | 884 | 879 | 947 | 971 | 1,005 | 1,034 | 1,140 | 1,239 | 1,368 | 1,357 |
| Other expenses | 1,117 | 1,455 | 1,654 | 1,425 | 1,352 | 1,734 | 1,691 | 1,383 | 2,072 | 1,818 | 2,480 | 2,504 |
| Total expenses | 3,617 | 4,143 | 4,371 | 4,034 | 4,143 | 4,717 | 4,808 | 4,511 | 5,538 | 5,664 | 6,798 | 6,807 |
| Operating profit | 1,102 | 1,631 | 2,084 | 1,461 | 1,388 | 1,906 | 2,089 | 1,982 | 1,732 | 2,157 | 1,911 | 1,896 |
| OPM % | 24.5% | 29.5% | 33.6% | 27.9% | 26.3% | 29.2% | 31.8% | 32.4% | 25.2% | 28.4% | 23.8% | 24.0% |
| Finance cost | 19.8 | 34.6 | 32.2 | 25.1 | 32.0 | 76.6 | 84.7 | 101 | 130 | 123 | 156 | 187 |
| Depreciation | 195 | 205 | 215 | 234 | 229 | 238 | 238 | 302 | 360 | 508 | 555 | 605 |
| Exceptional items | — | — | — | — | — | -220 | — | -34.2 | -84.9 | -398 | -18.2 | 1.3 |
| Profit before tax | 926 | 1,547 | 1,900 | 1,271 | 1,184 | 1,672 | 1,921 | 1,687 | 1,353 | 1,660 | 1,307 | 1,234 |
| Tax | 214 | 321 | 436 | 373 | 180 | 423 | 434 | 454 | 388 | 318 | 354 | 334 |
| Net profit | 790 | 1,246 | 1,483 | 920 | 1,026 | 1,244 | 1,521 | 1,239 | 1,023 | 1,341 | 990 | 928 |
| Profit to shareholders | 790 | 63.8 | 1,420 | 911 | 1,024 | 72.8 | 1,467 | 1,259 | 1,042 | 1,273 | 940 | 926 |
| EPS (₹) | 7.80 | 11.69 | 14.11 | 9.06 | 10.17 | 11.64 | 14.58 | 12.51 | 10.36 | 12.65 | 9.35 | 9.28 |
Profit & loss
Results for each year
8 financial years (April to March), consolidated, ₹ crore.
Sales, operating profit and net profit
FY19
FY20
FY21
FY22
FY23
FY24
FY25
FY26
Revenue · YoY (vs a year ago)
—+8.3%+6.0%+1.1%+13%+13%+19%+17%
Net profit · YoY (vs a year ago)
—-36%+81%+110%-56%-94%+30%+3,326%
RevenueOperating profitNet profitLine = trend
| ₹ Cr | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 13,166 | 14,253 | 15,102 | 15,265 | 17,237 | 19,547 | 23,242 | 27,148 |
| Other income | 201 | 114 | 37.2 | 225 | 187 | 284 | 270 | 510 |
| Total expenses | 10,985 | 12,508 | 12,650 | 12,765 | 14,230 | 15,008 | 17,265 | 20,520 |
| Employee cost | 2,124 | 2,415 | 2,490 | 2,434 | 2,766 | 3,138 | 3,681 | 4,418 |
| Operating profit | 2,973 | 2,420 | 3,136 | 3,453 | 3,256 | 5,370 | 6,839 | 7,959 |
| OPM % | 22.6% | 17.0% | 20.8% | 22.6% | 18.9% | 27.5% | 29.4% | 29.3% |
| Finance cost | 194 | 342 | 164 | 127 | 130 | 81.2 | 166 | 439 |
| Depreciation | 599 | 697 | 725 | 713 | 723 | 764 | 916 | 1,408 |
| Profit before tax | 2,382 | 1,495 | 2,285 | 2,838 | 2,590 | 4,809 | 6,027 | 6,621 |
| Tax | 530 | 320 | 147 | 512 | 588 | 978 | 1,412 | 1,595 |
| Tax rate % | 22.3% | 21.4% | 6.4% | 18.0% | 22.7% | 20.3% | 23.4% | 24.1% |
| Net profit | 1,899 | 1,204 | 2,185 | 4,618 | 2,092 | 3,973 | 4,673 | 5,124 |
| Profit to shareholders | 1,849 | 1,177 | 2,134 | 4,487 | 1,960 | 113 | 147 | 5,040 |
| Net margin % | 14.0% | 8.3% | 14.1% | 29.4% | 11.4% | 0.6% | 0.6% | 18.6% |
| EPS (₹) | 18.06 | 11.49 | 20.84 | 43.84 | 19.30 | 38.14 | 44.97 | 50.09 |
Balance sheet
Assets and debt
At each year end (and the latest half year), ₹ crore.
Equity, debt and assets
Mar 23
Mar 24
Mar 25
Mar 26
Sep 26
Shareholders' equity · YoY (vs a year ago)
—+13%+21%+13%—
Shareholders' equityBorrowingsCashLine = trend
| ₹ Cr | Mar 23 | Mar 24 | Mar 25 | Mar 26 | Sep 26 |
|---|---|---|---|---|---|
| Shareholders' equity | 17,516 | 19,830 | 23,953 | 27,111 | 27,817 |
| Long-term borrowings | 0.0 | 0.0 | 0.0 | 3,188 | 4,106 |
| Short-term borrowings | 1,163 | 769 | 3,170 | 8,582 | 9,143 |
| Total borrowings | 1,163 | 769 | 3,170 | 11,770 | 13,250 |
| Current liabilities | 5,527 | 5,340 | 9,042 | 15,712 | 18,024 |
| Fixed assets (PPE) | 5,697 | 5,803 | 6,042 | 9,231 | 9,276 |
| Inventories | 3,413 | 3,442 | 3,944 | 5,628 | 6,882 |
| Trade receivables | 4,417 | 5,220 | 4,025 | 5,416 | 4,381 |
| Cash & equivalents | 488 | 413 | 827 | 855 | 669 |
| Current assets | 10,008 | 11,420 | 17,046 | 19,906 | 18,434 |
| Total assets | 25,756 | 29,281 | 37,202 | 52,407 | 55,607 |
| Debt / equity | 0.07 | 0.04 | 0.13 | 0.43 | 0.48 |
Cash flow
Cash coming in and going out
For each financial year, ₹ crore. Free cash flow = cash from operations minus spending on fixed assets.
Operating, investing and financing cash
FY22
FY23
FY24
FY25
FY26
Operations · YoY (vs a year ago)
—+29%+20%+110%-69%
OperationsInvestingFinancingLine = trend
| ₹ Cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 2,078 | 2,689 | 3,228 | 6,777 | 2,117 |
| Cash from investing | 1,154 | 1,171 | -1,475 | -8,372 | -8,296 |
| Cash from financing | -868 | -4,400 | -1,804 | 2,031 | 5,997 |
| Spent on fixed assets | -1,203 | -1,031 | -907 | -1,713 | -3,394 |
| Free cash flow | 876 | 1,658 | 2,321 | 5,064 | -1,277 |
| Net cash flow | 2,364 | -540 | -51.7 | 435 | -182 |
Shareholding
Who holds the shares
Promoter and public holding at each quarter end, as filed with NSE.
Holding over time
Promoter & groupPublic
Latest (30 Sep 2026)
75.0%promoter
- Promoter & group
- 75.01%
- Public (FIIs, mutual funds, retail…)
- 24.99%
- Promoter change, last quarter
- 0.00 pts
Dividends & news
Latest dividends and announcements
Dividends & corporate actions
- Dividend - Re 1 Per Share
- Buy Back
- Dividend - Rs 11 Per Share
- Dividend - Rs 3 Per Share
- Buy Back
- Dividend - Rs 6 Per Share
- Dividend - Rs 2.50 Per Share
- Buyback
Board meetings
- ZYDUS LIFESCIENCES LIMITED has informed the Exchange about Board Meeting to be held on 04-Nov-2026 to inter-alia consider and approve the Unaudited F…
- the financial results for the period ended September 30, 2026
- ZYDUS LIFESCIENCES LIMITED has informed the Exchange about Board Meeting to be held on 11-Aug-2026 to inter-alia consider and approve the Unaudited F…
- the financial results for the period ended Jun 30, 2026
- Buyback.
Filings with NSE
- General Updates
- Analysts/Institutional Investor Meet/Con. Call Updates
- Press Release
- Analysts/Institutional Investor Meet/Con. Call Updates
- Analysts/Institutional Investor Meet/Con. Call Updates
- Copy of Newspaper Publication
- Analysts/Institutional Investor Meet/Con. Call Updates
Latest news
ZYDUSLIFE Outlook for the WeekEquitypandit · 8 Nov, 1:30 pmZydus Lifesciences Ends Zydus Sunshine Joint Venture DealHDFC Sky · 12 Nov, 9:49 amZydus Lifesciences completes 50% joint venture with Sunshine Healthcarescanx.trade · 12 Nov, 7:11 amZydus Lifesciences gains 2%, hits 52-week high in weak market; here's whyBusiness Standard · 28 Sep, 12:30 pmZydus Lifesciences shares fall 2.31% in early tradeMoneycontrol.com · 13 Aug, 12:30 pmZydus Lifesciences shares jump 2% to hit 52-week high as US FDA concludes inspection at New Jersey officeUpstox · 27 Sep, 12:30 pmZydus Lifesciences' Rs 1,100 crore share buyback at 13% premium: Check record date, other detailsThe Economic Times · 20 May, 12:30 pmZydus Lifesciences Share Price In Focus After Macquarie Maintains Outperform Rating. Here's WhyNDTV Profit · 27 Aug, 12:30 pmAbout
About Zydus Lifesciences Limited
Zydus Lifesciences Limited is listed on the NSE under the symbol ZYDUSLIFE and belongs to the Healthcare sector.
BRANDS
Company details
- Company name
- Zydus Lifesciences Limited
- NSE symbol
- ZYDUSLIFE
- BSE scrip code
- 532321
- ISIN
- INE010B01027
- Listed on
- NSE, BSE
- Series
- EQ (normal equity)
- Listed on NSE since
- 18 Apr 2000
- Face value
- ₹1 per share
- Market lot
- 1 share
- Shares issued
- 99.80 crore
- Index
- NIFTY 500
- Sector (NSE)
- Healthcare
- Industry
- Pharmaceuticals: Major
- Managing director / CEO
- Sharvil Patel
- Chair
- Pankaj Patel
- Headquarters
- Ahmedabad, Gujarat, India
- Registered address
- “Zydus Corporate Park”, Scheme No. 63, Survey No. 536, Near Vaishnodevi Circle, Khoraj (Gandhinagar), Sarkhej-Gandhinagar Highway, Ahmedabad-382481
- Founded
- 1952
- Employees
- 36,827
- Financial year
- April to March
- Results basis
- Consolidated
- Website
- zyduslife.com
Peers
Other Healthcare stocks
-
DIVISLABDivi's Laboratories
₹11,485.00
+1.04%
-
ALKEMAlkem Laboratories
₹5,302.00
-2.68%
-
GRANULESGranules India
₹840.50
+5.16%
-
SUNPHARMASun Pharmaceutical Industries
₹1,885.00
-0.91%
-
LAURUSLABSLaurus Labs
₹2,400.00
-1.19%
-
AUROPHARMAAurobindo Pharma
₹1,807.20
-1.11%
-
ACUTAASAcutaas Chemicals
₹3,996.10
+2.02%
-
APOLLOHOSPApollo Hospitals Enterprise
₹8,515.00
-1.03%
Prices from NSE via Upstox. Financials from the company's results filed with NSE (XBRL); ratios are our own working. Profile from global-stock-logos (MIT). For information only, not a recommendation to buy or sell.